^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    BIOMARKER:

    TP53 mutation + ATM mutation

    i
    Other names: TP53, Tumor Protein P53, Cellular Tumor Antigen P53, Phosphoprotein P53, Tumor Protein P53, Antigen NY-CO-13, Transformation-Related Protein 53, Mutant Tumor Protein 53, P53 Tumor Suppressor, Tumor Suppressor P53, Tumor Protein 53, BMFS5, TRP53, BCC7, LFS1, ATM, ATA, ATC, ATD, ATDC, TEL1, TELO1, ATM serine/threonine kinase
    Entrez ID:
    7157; 472
    Related biomarkers:
    Expression
    Mutation
    CNA
    Fusion
    Others
    1year
    Exploiting PRMT5 as a target for combination therapy in mantle cell lymphoma characterized by frequent ATM and TP53 mutations. (PubMed, Blood Cancer J)
    Co-targeting PRMT5, and ATR or CDK4 by using their inhibitors showed synergistic antitumor effects both in vitro and in vivo. Our results have provided a rational combination therapeutic strategy targeting multiple PRMT5-coordinated tumor-promoting processes for the treatment of R/R MCL with high mutation burdens.
    Journal • Combination therapy • Tumor mutational burden
    |
    TP53 (Tumor protein P53) • TMB (Tumor Mutational Burden) • ATM (ATM serine/threonine kinase) • CD19 (CD19 Molecule) • PRMT5 (Protein Arginine Methyltransferase 5)
    |
    TP53 mutation • TMB-H • ATM mutation • TP53 mutation + ATM mutation
    over1year
    Integrative Analysis of Genetic and Tumor Microenvironment Topology to Delineate Prognostic Subtypes in Mantle Cell Lymphoma (ASH 2022)
    Thus, this study suggests a new angle of ATM mutations in MCL pathogenesis which could improve risk stratification. Overall, this study may unravel distinct mechanisms of tumorigenesis with relevant clinical and biological implications.
    TP53 (Tumor protein P53) • ATM (ATM serine/threonine kinase) • CD8 (cluster of differentiation 8) • CCND1 (Cyclin D1) • STAT3 (Signal Transducer And Activator Of Transcription 3) • CD4 (CD4 Molecule) • NFKB1 (Nuclear factor of kappa light polypeptide gene enhancer in B-cells 1)
    |
    TP53 mutation • ATM mutation • CCND1 overexpression • ATM expression • ATM positive • TP53 mutation + ATM mutation
    over1year
    Clinical Implications of BRCA Mutations in Advanced Biliary Tract Cancer. (PubMed, Oncology)
    This study demonstrated that BRCA mutations might have a role as predictive biomarkers for palliative first-line platinum-based chemotherapy in patients with advanced BTC.
    Journal • BRCA Biomarker
    |
    HER-2 (Human epidermal growth factor receptor 2) • TP53 (Tumor protein P53) • FGFR3 (Fibroblast growth factor receptor 3) • ATM (ATM serine/threonine kinase) • NOTCH1 (Notch 1) • BRCA (Breast cancer early onset)
    |
    TP53 mutation • ATM mutation • BRCA mutation • TP53 mutation + ATM mutation
    almost2years
    SUBCLONAL ARCHITECTURE OF CHROMOSOMES REVEALED BY SINGLE-CELL ANALYSIS OF GENE EXPRESSION IN A PATIENT WITH CLONAL EVOLUTION OF RELAPSING/REFRACTORY CLL (EHA 2022)
    Such fact can be exploited to reconstruct chromosomal disruptions in individual cells using scRNAseq and to uncover the subclonal architecture of the disease. Grants: MH-CZ_AZV_NU20-08-00314, MH-CZ_AZV_NV19-03-00091, MEYS-CZ_MUNI/A/1330/2021, MH-CZ_RVO_65269705.
    Clinical • IO biomarker
    |
    TP53 (Tumor protein P53) • RB1 (RB Transcriptional Corepressor 1) • NOTCH1 (Notch 1) • BIRC3 (Baculoviral IAP repeat containing 3) • XPO1 (Exportin 1) • PIM1 (Pim-1 Proto-Oncogene) • ZMYM3 (Zinc Finger MYM-Type Containing 3)
    |
    TP53 mutation • ATM mutation • NOTCH1 mutation • Chr del(11q) • PIM1 mutation • TP53 mutation + ATM mutation
    2years
    Multiregion sequencing of sarcomatoid renal cell carcinoma arising from autosomal dominant polycystic kidney disease. (PubMed, Mol Genet Genomic Med)
    This highlights that common pro-oncogenic signals are present between ADPKD and sRCC providing insights into their shared pathobiology.
    Journal
    |
    TP53 (Tumor protein P53) • FLT3 (Fms-related tyrosine kinase 3) • CTNNB1 (Catenin (cadherin-associated protein), beta 1) • ARID1B (AT-Rich Interaction Domain 1B) • SMARCA2 (SWI/SNF Related, Matrix Associated, Actin Dependent Regulator Of Chromatin, Subfamily A, Member 2)
    |
    TP53 mutation • ATM mutation • CTNNB1 mutation • NF2 mutation • TP53 mutation + ATM mutation
    2years
    Clinicopathologic, genomic and immunophenotypic landscape of ATM mutations in non-small cell lung cancer (AACR 2022)
    Deleterious ATM mutations defined a subset of NSCLC with unique clinicopathologic, genomic, and immunophenotypic features.
    Clinical • PD(L)-1 Biomarker • IO biomarker
    |
    EGFR (Epidermal growth factor receptor) • PD-L1 (Programmed death ligand 1) • KRAS (KRAS proto-oncogene GTPase) • TP53 (Tumor protein P53) • ATM (ATM serine/threonine kinase) • STK11 (Serine/threonine kinase 11) • CDKN2A (Cyclin Dependent Kinase Inhibitor 2A) • CD8 (cluster of differentiation 8) • PD-1 (Programmed cell death 1) • RBM10 (RNA Binding Motif Protein 10) • KDM5C (Lysine Demethylase 5C) • FOXP3 (Forkhead Box P3)
    |
    PD-L1 expression • TP53 mutation • KRAS mutation • EGFR mutation • ATM mutation • TP53 wild-type • STK11 mutation • CDKN2A mutation • TP53 expression • ATM expression • TP53 mutation + ATM mutation
    |
    OncoPanel™ Assay